GeneDx published a study from Seattle Children's on expanding rapid genome sequencing beyond the ICU, finding that broader access to rapid genome sequencing was associated with a 35% diagnostic rate across pediatric inpatients, non-ICU inpatient wards had the highest diagnostic yield at 43%, and patients evaluated for faltering growth had the highest diagnostic yield at 63%.

We see a world where every genetic condition is understood, and every patient receives the care they need to live their healthiest life through genomics. ​ GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™, the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. ​ With over 25 years of innovation, more than 4,800 genetic diseases diagnosed, and over 1,000 scientific publications, we’re building the genomic intelligence network that’s shaping the future of precision medicine: for patients, providers, and partners alike.